Generated: May 25, 2017
|Title:||Method of lowering serum prolactin|
|Abstract:||Benzodiazepine derivatives which have tranquillizing activity, especially 1,4-benzodiazepine derivatives, can lower the serum prolactin concentration. They can reduce, dosage-dependently, the increase in the serum prolactin concentration induced by the administration of neuroleptics, which can lead to undesirable side-effects, when about 0.01 to 100 parts by weight of benzodiazepine derivatives are administered per part by weight of neuroleptic, it being immaterial whether the benzodiazepine derivative is administered before or after the neuroleptic or simultaneously therewith. The simultaneous administration of the active substances can be carried out as an ad hoc combination or in the form of a pharmaceutical combination.|
|Inventor(s):||Lotz; Wolfgang (Bad Krozingen, DE)|
|Assignee:||Hoffmann-La Roche Inc. (Nutley, NJ)|
Patent Claim Types:|
see list of patent claims
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.